Edesa Biotech Inc (EDSA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.14 (+0.00%), Market cap $0.10B, 52-week low–high $0.80 ~ $18.28.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate
Financial statements, price targets, institutional (13F) holdings and related news for Edesa Biotech Inc are updated in real time on BlackAll Trade.
Edesa Biotech Inc trades at $4.14 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Edesa Biotech Inc has a market cap of about $0.10B.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-rela